Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $776.57M |
| Gross Profit (TTM) | $724.04M |
| EBITDA | $-172.92M |
| Operating Margin | -23.40% |
| Return on Equity | -245.10% |
| Return on Assets | -16.30% |
| Revenue/Share (TTM) | $15.25 |
| Book Value | $1.59 |
| Price-to-Book | 131.04 |
| Price-to-Sales (TTM) | 13.94 |
| EV/Revenue | 13.93 |
| EV/EBITDA | -14.81 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 45.50% |
| Shares Outstanding | $52.38M |
| Float | $44.46M |
| % Insiders | 15.08% |
| % Institutions | 74.58% |
Volatility is currently contracting
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.
Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company's deep pipeline may help it launch newer products and post consistent revenue growth for a while.
AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXSM and any ticker you trade — then tracks every position and per-strategy win rate.
